Search results
Showing 136 to 150 of 284 results for diarrhoea
Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults who have not had ipilimumab.
Endoscopic full thickness removal of non-lifting colonic polyps (IPG580)
Evidence-based recommendations on endoscopic full thickness removal of non-lifting colonic polyps. This involves using a special device to remove the polyp and seal the bowel wall closed afterwards.
View recommendations for IPG580Show all sections
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)
Evidence-based recommendations on trametinib (Mekinist) with dabrafenib (Tafinlar) for adults with unresectable or metastatic melanoma that has a BRAF V600 mutation.
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)
Evidence-based recommendations on ipilimumab (Yervoy) for previously untreated advanced (unresectable or metastatic) melanoma in adults.
Evidence-based recommendations on aflibercept (Zaltrap) with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer after oxaliplatin-based chemotherapy in adults.
Acute diarrhoea in children: racecadotril as an adjunct to oral rehydration (ESNM12)
This evidence summary has been withdrawn because the product is no longer available in the UK.
Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (TA228)
Evidence-based recommendations on bortezomib (Velcade) and thalidomide (Thalidomide Celgene) for treating multiple myeloma in adults.
Dyspepsia and gastro‑oesophageal reflux disease in adults (QS96)
This quality standard covers investigating and managing symptoms of dyspepsia (indigestion) and gastro-oesophageal reflux disease (heartburn or reflux) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS96Show all sections
Sections for QS96
- Quality statements
- Quality statement 1: Advice to support self-management
- Quality statement 2: Urgent endoscopy
- Quality statement 3: Testing conditions for Helicobacter pylori
- Quality statement 4: Discussion about referral for non-urgent endoscopy
- Quality statement 5: Referral to a specialist service
- Update information
- About this quality standard
blood loss the rate of adverse events such as pain, vomiting and diarrhoea. It was unclear whether or not there was a difference in...
Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.
SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea (DG44)
We have moved Diagnostics guidance 44 to become HealthTech guidance 598. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)
Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of renal cell carcinoma in adults.
Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)
Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults.
Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)
Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults.
Evidence-based recommendations on avalglucosidase alfa (Nexviadyme) for Pompe disease.